Longer-versus shorter-duration dual-antiplatelet therapy after drug-eluting stent placement a systematic review and meta-analysis

Annals of Internal Medicine

Volumn 163, Issue 2, 2015, Pages 118-126

  Spencer, Frederick A ^a   Prasad, Manya ^b   Vandvik, Per O ^c   Chetan, Devin ^a   Zhou, Qi ^d   Guyatt, Gordon ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b MAHARSHI DAYANAND UNIVERSITY   (India)

^c NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICAGRELOR;

ANTICOAGULANT THERAPY; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; EMBASE; HEART INFARCTION; HUMAN; INFORMATION RETRIEVAL; LONG TERM CARE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; BLEEDING; CAUSE OF DEATH; CHEMICALLY INDUCED; DEVICES; DRUG ADMINISTRATION; DRUG COMBINATION; MORTALITY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; REOPERATION;

CAUSE OF DEATH; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; REOPERATION; RISK ASSESSMENT;

EID: 84938234622     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-0083     Document Type: Review

References (38)

1. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, et al; ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholineencapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114:798-806. [PMID: 16908773]
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-23. [PMID: 14523139]
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-31. [PMID: 14724301]
4. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al; Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-619. [PMID: 25173339] doi:10.1093/eurheartj/ehu278
5. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574-651. [PMID: 22064601] doi:10.1161/CIR.0b013e31823ba622
6. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, et al; American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e637S-68S. [PMID: 22315274] doi:10.1378/chest.11-2306
7. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-78. [PMID: 17321312]
8. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcomes after drugeluting stent implantation. JAMA. 2007;297:159-68. [PMID: 17148711]
9. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-91. [PMID: 17174201]
10. Faxon DP, Lawler E, Young M, Gaziano M, Kinlay S. Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study. Circ Cardiovasc Interv. 2012;5:372-80. [PMID: 22668555] doi:10.1161/CIRCINTERVENTIONS.111.967257
11. Collet JP, Silvain J, Barthélémy O, Rangé G, Cayla G, Van Belle E, et al; ARCTIC investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet. 2014;384:1577-85. [PMID: 25037988] doi: 10.1016/S0140-6736 (14) 60612-7
12. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, et al; OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310:2510-22. [PMID: 24177257] doi:10.1001/jama.2013.282183
13. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125:505-13. [PMID: 22179532] doi:10.1161/CIRCULATIONAHA.111.059022
14. Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation. 2014;129:304-12. [PMID: 24097439] doi:10.1161/CIRCULATIONAHA.113.003303
15. Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, et al. Duration of dual antiplatelet therapy after implantation of drugeluting stents. N Engl J Med. 2010;362:1374-82. [PMID: 20231231] doi:10.1056/NEJMoa1001266
16. Valgimigli M, Borghesi M, Tebaldi M, Vranckx P, Parrinello G, Ferrari R; PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J. 2013;34:909-19. [PMID: 23315904] doi:10.1093/eurheartj/ehs460
17. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al; DAPT Study Investigators. Twelve or 30 monthsj of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155-66. [PMID: 25399658] doi:10.1056/NEJMoa 1409312
18. Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ. 2007;334:786. [PMID: 17403713]
19. Lim E, Brown A, Helmy A, Mussa S, Altman DG. Composite outcomes in cardiovascular research: a survey of randomized trials. Ann Intern Med. 2008;149:612-7. [PMID: 18981486]
20. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al; Cochrane Bias Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. [PMID: 22008217] doi:10.1136/bmj.d5928
21. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6. [PMID: 18436948] doi:10.1136/bmj.39489.470347. AD
22. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol. 2011;64:407-15. [PMID: 21247734] doi:10.1016/j.jclinepi.2010.07.017
23. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol. 2011;64:1283-93. [PMID: 21839614] doi:10.1016/j.jclinepi.2011.01.012
24. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al; GRADE Working Group. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol. 2011;64:1294-302. [PMID: 21803546] doi:10.1016/j.jclinepi.2011.03.017
25. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al; GRADE Working Group. GRADE guidelines: 8. Rating the quality of evidence-indirectness. J Clin Epidemiol. 2011;64:1303-10. [PMID: 21802903] doi:10.1016/j.jclinepi.2011.04.014
26. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence-publication bias. J Clin Epidemiol. 2011;64:1277-82. [PMID: 21802904] doi:10.1016/j.jclinepi.2011.01.011
27. Akl EA, Johnston BC, Alonso-Coello P, Neumann I, Ebrahim S, Briel M, et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One. 2013;8:e57132. [PMID: 23451162] doi:10.1371/journal.pone.0057132
28. Akl EA, Briel M, You JJ, Sun X, Johnston BC, Busse JW, et al. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ. 2012;344:e2809. [PMID: 22611167] doi:10.1136/bmj.e2809
29. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al; RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60:1340-8. [PMID: 22999717] doi:10.1016/j.jacc.2012.06.043
30. Gilard M, Barragan P, Noryani AA, Noor HA, Majwal T, Hovasse T, et al. 6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015;65:777-86. [PMID: 25461690] doi:10.1016/j.jacc.2014.11.008
31. Borenstein MH, Hedges LV, Higgins J PT, Rothstein HR. Introduction to Meta-analysis. Chichester, United Kingdom: J Wiley; 2008.
32. Int Hout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25. [PMID: 24548571] doi:10.1186/1471-2288-14-25
33. Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N, et al. Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64:2086-97. [PMID: 25236346] doi:10.1016/j.jacc.2014.09.008
34. Schulz-Schüpke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, et al; on behalf of the Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) trial investigators. ISAR-SAFE: a randomized, double-blind, placebocontrolled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015. [PMID: 25616646]
35. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119:3198-206. [PMID: 19528338] doi:10.1161/CIRCULATIONAHA.108.826479
36. Kirtane AJ, Leon MB, Ball MW, Bajwa HS, Sketch MH Jr, Coleman PS, et al; ENDEAVOR IV Investigators. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimuseluting stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv. 2013;6:325-33. [PMID: 23523453] doi:10.1016/j.jcin. 2012.12.123
37. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, et al; SPIRIT IV Investigators. Everolimus-eluting versus paclitaxeleluting stents in coronary artery disease. N Engl J Med. 2010;362:1663-74. [PMID: 20445180] doi:10.1056/NEJMoa0910496
38. Palmerini T, Benedetto U, Bacchi-Reggiani L, Riva DD, Biondi-Zoccai G, Feres F, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015. [PMID: 25777667] doi:10.1016/S0140-6736 (15) 60263-X